20 June 2013
Keywords: bzl101, advance, into, ph, ii, trials, drug
Article | 09 June 2008
US drug developer Bionovo reported encouraging data from an ongoing trial of BZL101, an oral drug candidate, in patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 June 2008
19 June 2013
© 2013 thepharmaletter.com